The MarketWatch News Department was not involved in the creation of this content. WILMINGTON, Del., July 24, 2024 /PRNewswire-PRWeb/ -- SPI Pharma introduces Valens(TM) as a new portfolio brand name ...
SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that the pivotal Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory compound (ebselen), for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback